* Based on the trial product estimand: estimated efficacy in an idealized scenario in which all patients stayed on treatment and took no other weight loss therapies ** Based on the treatment policy estimand: estimated efficacy regardless of whether patients stayed on treatment or took other weight loss therapies About CagriSema CagriSema is being investigated by Novo Nordisk as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE program) and as a treatment for adults with type 2 diabetes (REIMAGINE program)
Requires a 20 minute consultation with a provider, which includes a physical assessment and health history to ensure safe prescribing and administration
Freeze at -20 degrees Celsius only for long-term storage of vials that will not be opened for an extended period, and avoid repeated freeze-thaw cycles
These mechanistic domains position GLP-3 Cagrilintide research peptide as a key substrate for studying multi-hormonal metabolic signaling , energy-balance regulation , and integrated incretin-amylin pathways
Why Researchers Choose Summit Pep Labs 99% HPLC-verified purity Cu:peptide stoichiometry verified not just peptide purity LC-MS identity confirmation Batch consistency and traceability Professional labeling and packaging Research-grade manufacturing standards Secure shipping and quality assurance Commitment to reproducibility and reliability Frequently Asked Questions What is GHK-Cu
Ayala A, Muoz MF, Argelles S
